Inhibidores de la integrasa y raltegravir en el manejo de la infección por vírus de la inmunodeficiencia humana en la era de la resistencia a múltiples medicamentos: [revisión] / Integrase Inhibitors and raltegravir use in the management of HIV infection in the era of multidrug resistance: [review]
Immunodeficiency virus infection in humans (HIV) has generated a worldwide impact exceeding initial estimates for this disease. At present, it is necessary to search for new antiretroviral drugs within the families of known medication, but the search for new therapeutic objectives under the effect of medication which has not been exposed to the virus and, therefore without natural resistance to it, is even more important. Integrase inhibitors are the family of antiretroviral medication most recently approved for clinical use; raltegravir is a new drug with important attributes that make it a tool to be considered in rescue regimens, change therapies, and naïve patient particular cases.